HLS Therapeutics (TSE:HLS) Stock Price Down 4.3% - Time to Sell?

HLS Therapeutics Inc. (TSE:HLS - Get Free Report) fell 4.3% on Wednesday . The stock traded as low as C$3.76 and last traded at C$3.77. 1,592 shares changed hands during trading, a decline of 93% from the average session volume of 24,348 shares. The stock had previously closed at C$3.94.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus decreased their price target on HLS Therapeutics from C$3.75 to C$3.25 in a research note on Tuesday, August 13th.

HLS Therapeutics Trading Down 1.9 %

The company has a market capitalization of C$117.62 million, a price-to-earnings ratio of -3.66 and a beta of 1.07. The company has a current ratio of 2.02, a quick ratio of 1.01 and a debt-to-equity ratio of 100.44. The business's 50 day moving average price is C$3.34 and its two-hundred day moving average price is C$3.72.

HLS Therapeutics (TSE:HLS - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported C($0.25) earnings per share for the quarter, meeting analysts' consensus estimates of C($0.25). The firm had revenue of C$19.87 million for the quarter, compared to analyst estimates of C$19.25 million. HLS Therapeutics had a negative net margin of 40.90% and a negative return on equity of 24.82%. On average, equities analysts predict that HLS Therapeutics Inc. will post -0.12 earnings per share for the current fiscal year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.